Skip to main content
. Author manuscript; available in PMC: 2012 Feb 4.
Published in final edited form as: Nat Med. 2011 Jun 26;17(7):875–882. doi: 10.1038/nm.2377

Figure 4.

Figure 4

Cdk1 depletion or inhibition protects non-transformed cells from PARP inhibitor treatment. (a) Colony formation of cell lines treated with DMSO or RO-3306 and AG014699. Mean ± SE LC50 values for AG014699 from DMSO (D)- or RO-3306 (R)-treated cells. *, P ≤ 0.003. (b) Colony formation of RPE and NCI-H1299 cells treated with scrambled siRNA (Scr) or cdk1 siRNA prior to treatment with AG014699 for 72 hours followed by replating for colony formation. *, P = 0.018. (c) Cell cycle profiles (left) and TUNEL-positive (middle) NCI-H1299 cells transfected with scrambled siRNA (Scr) or cdk1 siRNA for 48 hours, and subsequently treated with DMSO or AG014699 for the indicated times. (Right) Mean percent of TUNEL-positive cells ± SE at 120 hrs over three experiments. *, P = 0.0191. (d) Western blot analyses of cells treated as in (c) after 24 hours AG014699 treatment. (e) Viability of HS578T and HS578Bst cell lines treated with DMSO or RO-3306 and increasing concentrations of AG014699. (f) Viability of HS578T and HS578TBst cell lines treated with DMSO or AG024322 and AG014699. *, P = 0.0023.